α-L-fucosidase (AFU) is a lysosomal acid hydrolase widely found in various tissues, blood, and bodily fluids of the human body. Its primary function is to catalyze the hydrolysis of large molecules such as glycoproteins and glycolipids containing fucose residues, thus participating in complex metabolic processes. 

AFU not only plays an essential role under normal physiological conditions but also exhibits unique diagnostic value in various diseases. Particularly noteworthy is its role in the early screening and diagnosis of liver cancer. Studies have shown that AFU has a sensitivity and specificity of 75% and 90%, respectively, in diagnosing liver cancer, higher than traditional tumor markers like alpha-fetoprotein (AFP). Moreover, combined detection of AFU and AFP can increase the sensitivity of diagnosing primary liver cancer to 91.30%, with an accuracy rate reaching 91.04%, significantly reducing the likelihood of missed diagnoses and enhancing diagnostic precision and comprehensiveness.

Just as specific molecular probes need to precisely bind to target proteins, high-quality AFU substrates are indispensable for achieving precision medicine. Choosing the right substrate is akin to finding the most compatible molecular partner for fucosidase, making each test more accurate and reliable. Below are some AFU substrate series products independently developed and produced by Geneseqtools Biotechnology: